Filing Details
- Accession Number:
- 0001209191-22-018188
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-11 16:58:59
- Reporting Period:
- 2022-03-10
- Accepted Time:
- 2022-03-11 16:58:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1434316 | Fate Therapeutics Inc | FATE | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1238362 | John Mendlein | C/O Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego CA 92131 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-03-10 | 31,562 | $1.63 | 191,017 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-03-10 | 19,493 | $34.73 | 171,524 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-03-10 | 12,069 | $35.48 | 159,455 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-03-10 | 31,562 | $0.00 | 31,562 | $1.63 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2022-03-12 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021.
- Represents the weighted average sale price of the shares sold from $34.12 to $35.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 3.
- Represents the weighted average sale price of the shares sold from $35.13 to $35.75 per share.
- This option is fully vested.
Billionaire Hedge Funds
